PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION.

Trial Profile

PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2012

At a glance

  • Drugs Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Acronyms REVIR
  • Most Recent Events

    • 11 Dec 2011 Status changed from recruiting to active, no longer recruiting. Overall, 37 patients were recruited and 10 months follow-up completed.
    • 11 Dec 2011 Results were reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top